Neurochem: Another Failed Small Cap Biotech
August 27, 2007 by Douglas A. McIntyreShares in Neurochem (NRMX) are down 30% today to a 52-week low of $3.70.
According to The Associated Press "its Alzheimer’s disease treatment candidate failed in a late-stage clinical trial."
NRMX shares traded as high as $26.51 during the last 52 weeks. Of course, they probably never belonged there. At that share price, the company had a market cap of almost $1.2 billion. Last year, NRMX lost over $66 million on under $3 million in revenue.
The higher share price never made any sense.
Douglas A. McIntyre
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.